**Author details**

David Vrabel<sup>1</sup> , Adela Souckova1 , Lenka Sedlarikova2 and Sabina Sevcikova1 \*

\*Address all correspondence to: sevcik@med.muni.cz

1 Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

[12] Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1. Blood. 2011;**117**(18):4691-4695 [13] Sedlarikova L, Kubiczkova L, Kryukov F, Pelcova J, Adam Z, Pour L, et al. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc,

Liquid Biopsies in Multiple Myeloma http://dx.doi.org/10.5772/intechopen.78630 79

[14] Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. International

[15] Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;**101**(11):4569-4575

[16] Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

[17] Weinhold N, Chavan SS, Heuck C, Stephens OW, Tytarenko R, Bauer M, et al. High risk multiple myeloma demonstrates marked spatial genomic heterogeneity between focal lesions and random bone marrow; implications for targeted therapy and treatment

[18] Kubaczkova V, Vrabel D, Sedlarikova L, Besse L, Sevcikova S. Cell-free DNA - minimally invasive marker of hematological malignancies. European Journal of Haematology.

[19] Qasaimeh MA, Wu YC, Bose S, Menachery A, Talluri S, Gonzalez G, et al. Isolation of circulating plasma cells in multiple myeloma using CD138 antibody-based capture in a microfluidic device. Scientific Reports. 2017;**7**:45681; 04 12/14/received 03/02/accepted [20] Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nature

[21] Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, et al. Circulating serum microRNA-130a as a novel putative marker of extramedullary myeloma. PLoS

[22] Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, et al. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. European

[23] Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, et al. Clonal circulating cells are common in plasma cell proliferative disorders: A comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma,

[24] Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with

newly diagnosed multiple myeloma. Blood. 2005;**106**(7):2276-2279

Czechoslovakia. 2015;**159**(4):554-561

Nature Communications. 2017;**8**(1):268

resistance. Blood. 2015;**126**:20-20

Communications. 2017;**8**:15086

Journal of Haematology. 2017;**99**(3):223-233

and active myeloma. Blood. 1996;**88**(1):289-296

One. 2015;**10**(9):e0137294

2017;**99**(4):291-299

Journal of Clinical Oncology. 2015;**20**(3):413-422

2 Department of Immunology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
